Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Shinjuku-ku, Tokyo, 162-0822, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who are beginning to receive the treatment with ORENCIA Subcutaneous Injection 125mg Syringe 1mL under the approved indications, dosage, and administration

Treatment and study plan

Orencia

Drug

Primary outcomes

Safety measured by number of Adverse events and laboratory abnormalities associated with adverse events

Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Collaborators

Ono Pharmaceutical Co., Ltd.

Registry information

Official study title

Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Important dates

Study start: 2013
Primary completion: 2016
Study completion: 2016
First posted: Nov 9, 2015
Registry last updated: Jan 13, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed